ArticleJournal of immunology research2018
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.
Article in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- From production to bedside: A tiered QC framework for regulatory alignment and analytical comparability in decentralized CGT.Regenerative therapy · 2026Review
- Efficacy of treatment with tumor-infiltrating lymphocytes as adoptive cell therapy: an integrative review.Einstein (Sao Paulo, Brazil) · 2024Review
- Revisiting the melanomagenic pathways and current therapeutic approaches.Molecular biology reports · 2022Review
- Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets.Medicinal research reviews · 2022Review
- Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives.Molecular therapy oncolytics · 2021Review
- Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility.Journal of surgical oncology · 2021Article
- Colorectal Cancer, Liver Metastases and Biotherapies.Biomedicines · 2021Review
- Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.Oncoimmunology · 2021Article
- Graft-versus-cancereffect and innovative approaches in thetreatment of refractory solid tumorsTurkish journal of medical sciences · 2020Review
- Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8Cancer immunology, immunotherapy : CII · 2020Article
- Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy.Cancers · 2020Review
- Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-1ChemMedChem · 2020Article
- TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer.Journal of immunology research · 2020Article
- Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.Journal of immunology research · 2020Article
- Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments.International journal of molecular sciences · 2019Review
- Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma.Frontiers in immunology · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma. All advanced melanoma patients treated with TILs using the same TIL expansion methodology and same treatment interleukin-2 (IL-2) regimen between 2009 and 2012 were included. After sterile intralesional excision of a cutaneous or subcutaneous metastasis, TILs were produced according to a previously described method and then infused into the patient who also received a complementary subcutaneous IL-2 regimen. Nine women and 1 man were treated for unresectable stage IIIC (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.